

Neurotech to present at the Ignite Investment Summit Hong Kong

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to advise of its participation at the Ignite Investment Summit being held this week in Hong Kong.

Managing Director & CEO Dr Anthony Filippis will discuss the Company's broad-spectrum oral cannabinoid therapy, NTI164, as a novel therapy for childhood neurological and neurodevelopmental disorders.

In addition to numerous individual investor meetings at the event, Dr Filippis will deliver a group presentation at 3:10pm HKT/5:10pm AEST on Wednesday 15 April 2026.

A copy of the presentation is attached.

Authority

This announcement was authorised for release by Anthony Filippis, Managing Director and CEO of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.



Dr Anthony Filippis
Chief Executive Officer & Managing Director

Redefining Treatment for Neurodevelopmental Disorders

Corporate Overview

Ignite Investment Summit, Hong Kong

April 2026 | ASX: NTI



Neurotech
International



Forward-Looking Statements

This presentation includes forward looking statements. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guidance” and other similar expressions. Indications of, and guidance on, future earnings or dividends and financial position and performance are also forward-looking statements.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.


The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company’s expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavour our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflict in Ukraine.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Neurotech: a high value investment opportunity



Neurotech is an ASX-listed (ASX: NTI) clinical-stage biotech company

Market cap of ~\$18m and cash at 31 Dec 2025 of \$6.3m

Phase 3 clinical trial program in autism spectrum disorder (ASD)

Placement to raise ~\$4m in Dec 2025

R&D Tax rebate \$4.73m in Nov 2025



Neurotech is developing NTI164 as a novel therapy for childhood neurological and neurodevelopmental disorders (NDD)

NTI164 targets neuroinflammation

It modulates microglia (the immune cells of the brain) to dampen their overactive inflammatory state in NDD

Data published in peer-reviewed scientific journals

Demonstrated clinical safety and efficacy in ASD, Rett syndrome and PANS



With four completed clinical trials across three indications, NTI164 moves into a Phase 3 clinical trial in ASD

Orphan drug and rare pediatric disease designations granted by US FDA and European EMA

Competitive landscape not crowded with few approved therapies in our target indications

Progressing global regulatory plans and partnering discussions

Targeting areas of significant unmet medical need. Epidiolex selling ~\$1b per year for two forms of epilepsy^[1]

^[1] [Jazz Pharmaceuticals full year 2025 financial results](#)

Targeting high impact indications where there is a clear unmet market need



autism spectrum disorder (ASD)

- 1 in 31 children (US)
- Boys 4x more likely to be diagnosed
- Global ~62M^[1]

- High unmet need for safe, effective treatments for core symptoms
- Current market ~US\$3B^[2] and growing
- Growing recognition by regulators



Rett syndrome

- Rare disease ~1 in 10,000-15,000 girls
- ~6,000-9,000 in US alone
- Global ~350,000^[3]

- High value orphan indication
- One FDA-approved drug (Daybue) with US\$375k/year pricing^[4]
- Net product sales US\$348M^[5]
- Accelerated regulatory pathways



PANS/PANDAS

- Emerging diagnosis
- ~1 in 200 in US alone^[6]
- Global cases not well defined

- No approved treatments
- Often misdiagnosed; high severity and family impact
- Fast-track potential if recognised

^[1] [The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021](#)

^[2] [Research and Markets Autism Spectrum Disorders Market Report 2025](#)

^[3] [Rett Syndrome: Crossing the Threshold to Clinical Translation](#)

^[4] [Neuren Pharmaceuticals 2022 Annual Report](#)

^[5] [Acadia Pharmaceuticals Full Year 2024 financial results 26 Feb 2025](#)

^[6] [PANDAS network](#)

Neurotech's pipeline comprises clinical programs in neurodevelopmental disorders of children where neuroinflammation is involved


NTI164

Targets neuroinflammation

Neurodevelopmental disorders



Autism Spectrum Disorder




PI:
Prof Michael Fahey



✓ Phase I/II data
✓ Phase II/III data



PANS/PANDAS




PI:
Prof Russell Dale



✓ Phase I/II data



Cerebral Palsy



HREC approval &
CTN clearance

Program on hold following strategic review

Phase I/II

Rare neurodevelopmental disorders



Rett Syndrome



PI:
Prof Carolyn Ellaway



✓ Phase I/II data

Other indications

Undisclosed indications



Opportunities in other neuroinflammatory indications

NTI164 – Clinical Data Demonstrated Improvements

Across three clinical studies in Autism and Rett syndrome, NTI164 consistently improved the outcomes that matter most to families.

THE FOUR PILLARS OF CHANGE

Phase II/III HARMONY Autism Spectrum Disorder Clinical Trial

GLOBAL SYMPTOM SEVERITY

84%

of patients showed improvement within the first 8 weeks of NTI164 treatment

- Children moved down in illness severity ratings.
- Clinicians rated clinically meaningful overall improvement.

Measured by the Clinical Global Impression of Improvement (CGI-I) scale

COMMUNICATION & COGNITIVE ENGAGEMENT

- Better engagement.
- More alertness.
- More expressive behaviour.

Measured by the Vineland-3

+3.23

in the Vineland-3 - a meaningful improvement in communication ability

-3.064

reduction in social challenges – a meaningful improvement in social responsiveness

SOCIAL ENGAGEMENT

- Improved social responsiveness and interaction.
- Greater engagement with caregivers.

Measured by the SRS-2

ANXIETY REDUCTION

- Reduced anxiety.
- Improved mood regulation.
- Fewer behavioural disturbances.


Measured by the ADAMS scale

39%

improvement in anxiety scores

When communication improves, anxiety decreases, and families feel relief – that is significance.


Approval for Phase III BEYOND HARMONY clinical trial in ASD



*Adaptive design

ASD Phase III roadmap and value inflection points

For personal use only



Phase III program supported by clinical data:

- Statistically significant and clinically meaningful Phase II/III efficacy signals
- Consistent safety profile across prior clinical exposure
- TGA/FDA-aligned registration endpoints
- Large unmet market need – no approved therapies for core ASD symptoms
- Scalable, commercially viable formulation
- Partnering discussions with pharmaceutical and biotechnology companies ongoing

Note: The above roadmap is a statement of current intentions as at the date of this presentation. Intervening events may alter the timing, sequence or feasibility of the matters described. Accordingly, there can be no assurance that the milestones outlined will be achieved within the anticipated timeframes, or at all.

The company has commenced a broad outreach program to socialise and nurture potential future partners for NTI164

For personal use only

Typical Structure of Pharma Partnering Transactions

Upfront

- Payment(s) at the time signing a deal
- Usually not ‘at risk’
- May include an equity component

Milestones

- Payment(s) during the partnership, linked to pre-defined development and commercial outcomes
- ‘At risk’ payments – not made if the relevant objectives are not met

Royalties

- A share of net sales (or sometimes profit) that flows from the licensee to the licensor
- Often the greatest source of economic value in the transaction
- Value depends on successful commercialisation of the product

Benchmarks for Phase II/III Neuro Disease Partnering Transactions (2016 – 2025 YTD) (n=64)

	Low	Median	High
Upfront Cash/Equity (US\$M)	3	40	1000
Milestones (US\$M)	120	467	1,900
Royalties	5%	9%	12%

The capability and commitment of a partner to develop and commercialise the product can be as crucial as the financial terms of the transaction

Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential

Licensing Transactions						
Licensee	Licensor	Key Asset(s)	Key Indication(s)	Stage	Date	Deal Value (US\$)
 NOVARTIS	 PTC THERAPEUTICS	PTC518	Huntington's disease	Phase II	Nov 2024	\$2.9B
 ABVC BIOPHARMA	 AI BTL BIOPHARMA	ABV-1504/1505	ADHD, depression	Phase II	Nov 2023	\$667M
 ACADIA	 neuren pharmaceuticals	Trofinetide (xUS), NNZ-2591	Rett syndrome (ex-US)	Phase II	Jul 2023	\$931M
 sanofi	MAZE THERAPEUTICS	MZE-001	Pompe disease	Phase I	May 2023	\$750M
 ACADIA	 saniona	SAN711	Essential tremor	Phase I	Nov 2024	\$582M
 NS Pharma	 Capricor Therapeutics	CAP-1002 (United States)	Duchenne muscular dystrophy	Phase II	Jan 2022	\$735M
 STALICLA	 NOVARTIS	Mavoglurant	Autism, mood disorders	Phase II	Jan 2023	\$270M
M&A Transactions						
Acquirer	Target	Key Asset(s)	Key Indication(s)	Stage	Date	Deal Value (US\$)
 Pfizer	 ARENA PHARMACEUTICALS	Olorinab (cannabinoid)	Immuno-inflammatory disorders	Phase II	Dec 2021	\$6.7B
 Jazz Pharmaceuticals	 GW pharmaceuticals	Epidiolex (cannabinoid)	Dravet, Lennox Gastaut syndromes	Approved	Feb 2021	\$7.2B
 Biogen	 REATA PHARMACEUTICALS	Skyclarus	FA, neurological disorders	Approved	Jul 2023	\$7.3B

Source: Non-exhaustive list, DealForma, company press releases, Neurotech research

Neurotech financial position and value drivers

For personal use only

Corporate Fundamentals

Market Capitalisation:	~AU\$ 18.2M
Primary Listing:	ASX: NTI
Shares on Issue:	1.30 Billion

Cash Position

Cash Balance (31 Dec 25):	AU\$6.3 Million
---------------------------	-----------------

Shareholders

Top 40 (31 Jan 26)	54.01%
--------------------	--------

Analyst Coverage



Huge Market Potential

Addressing high-growth neurological markets

Proven science and de-risked programs

Positive clinical results supporting efficacy & safety

Clear Commercial Pathway

Strong IP, regulatory and commercial path

Strong Leadership & Vision

Experienced team driving execution

Value-driving catalysts on the horizon

For personal use only

CY2026		
Human Research Ethics Committee approval for ASD registration-enabling study	1Q CY2026	
Initiation of first clinical site	1Q CY2026	
First patient enrolled in ASD clinical trial	Mid CY2026	
Long-term chronic toxicology data	Mid CY2026	
IND submission for ASD	1H CY2026	
IND submission Rett syndrome	1H CY2026	
ASD registration-enabling data readout	Late CY2026	

Note: The above roadmap is a statement of current intentions as at the date of this presentation. Intervening events may alter the timing, sequence or feasibility of the matters described. Accordingly, there can be no assurance that the milestones outlined will be achieved within the anticipated timeframes, or at all.



Thank You & Contact Details



Neurotech Investor Relations:

info@neurotechinternational.com

www.neurotechinternational.com

This presentation was approved for release by the Board



Neurotech
International



Neurotech
International